Company / Cost of Revenue
Biogen Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$2.4B
FY2025
5-year range
$2.1B / $2.5B
FY2021-FY2025
Trend
+4.1%
vs FY2024
Sector context
#14 of 83
Health Care
What the data says
Biogen's cost of revenue of $2.4B is higher than 83% of companies in the Health Care sector (FY2025). Cost of Revenue has fluctuated over the past 10 years, ranging from $1.5B in FY2016 to $2.5B in FY2023.
Based on SEC 10-K filings.
$2.4B in FY2025 with a 5-year CAGR of +5.9%. Top quartile in the Health Care sector.
Improved from $2.5B to $2.4B over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +1.8%
- 5-Year CAGR
- +5.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 17% in Health CareTop 83% of 83This company $2.4B Sector average $2.0B
▼
+19.1% above sector average
Key checks
Key Insights
- 5-year CAGR of +5.9%, indicating consistent growth.
- In FY2025, cost of revenue increased 4.1% year-over-year.
- Ranks #14 out of 83 companies in the Health Care sector.
- Peak cost of revenue was recorded in FY2023.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.4B | +4.1% |
| FY2024 | $2.3B | -8.8% |
| FY2023 | $2.5B | +11.2% |
| FY2022 | $2.3B | +8.0% |
| FY2021 | $2.1B | +16.9% |
| FY2020 | $1.8B | -7.7% |
| FY2019 | $2.0B | +7.7% |
| FY2018 | $1.8B | +11.4% |
| FY2017 | $1.6B | +10.2% |
| FY2016 | $1.5B | +19.2% |
As of FY2025 · SEC 10-K · Updated Mar 3, 2026